While ibogaine isn’t yet FDA-approved and carries risks, this funding reflects a shift in how policymakers view addiction treatment—prioritizing bold, science-backed solutions over traditional approaches. For Texans battling addiction, it could mean new hope on the horizon. For the rest of the country, it’s another sign that psychedelic medicine is going mainstream.

Texas is stepping into the spotlight of psychedelic research by approving $50 million to study ibogaine, a plant-based substance with potential to treat addiction and PTSD. This move signals a growing openness to alternative therapies, especially for veterans and those struggling with opioid dependence.